[
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_0",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal cancer screening: 50–75 (A); 45–49 (B); 76–85 selective offer individualized (C)",
    "chunk_index": 0
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_6",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Stool-based colorectal screening: FIT, sDNA‑FIT vs gFOBT accuracy; annual testing and colonoscopy follow-up",
    "chunk_index": 6
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_3",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Screening net benefit: age 50–75 high‑certainty substantial; 45–49 moderate‑certainty moderate",
    "chunk_index": 3
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_8",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Screen at age 45; rising incidence in <50 cohorts; harms rise with age; limited gain >75",
    "chunk_index": 8
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_9",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Adults ≥86: screening unlikely to benefit; recommended CRC test intervals (FIT, sDNA‑FIT, CT, sigmoidoscopy, colonoscopy)",
    "chunk_index": 9
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_10",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "CRC disparities by race: access/quality gaps drive higher Black incidence/mortality; early-onset rise in White/Hispanic",
    "chunk_index": 10
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_2",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal cancer screening: recommended tests and intervals for adults 50–75; selective 76–85",
    "chunk_index": 2
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_4",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Age 76–85 screening: moderate certainty, greater benefit if never screened; excludes serum/urine/capsule tests",
    "chunk_index": 4
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_5",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Age and demographic colorectal cancer risk; prefer stool and visualization tests; exclude serum/urine/capsule",
    "chunk_index": 5
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_1",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Average-risk adults ≥45: USPSTF colorectal cancer screening grades — 45–49 B; 50–75 A; 76–85 C",
    "chunk_index": 1
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_12",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Black adults: systems to ensure adherence to stool-based CRC screening and follow-up colonoscopy",
    "chunk_index": 12
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_14",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Updated colorectal cancer screening: benefits, test accuracy, harms, age-subgroup review",
    "chunk_index": 14
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_15",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "CISNET modeling: age-based benefit/harm, elevated-risk and race analyses; single-application test accuracy vs colonoscopy",
    "chunk_index": 15
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_17",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Accuracy of colonoscopy and CT colonography for detecting ≥10 mm adenomas; age-related sensitivity trend",
    "chunk_index": 17
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_19",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colonoscopy/FIT cohort evidence of colorectal cancer mortality reduction, age-specific benefit",
    "chunk_index": 19
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_18",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Adults age 50+: RCTs—flexible sigmoidoscopy and biennial gFOBT reduce colorectal cancer mortality",
    "chunk_index": 18
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_13",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal cancer screening: stool-test collection rules, positive-result colonoscopy, interval differences",
    "chunk_index": 13
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_21",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Adults 45–75 colorectal screening model: LYG/cases/deaths averted per 1000; colonoscopy bleeding/perforation per 10,000",
    "chunk_index": 21
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_22",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Screening colonoscopy adverse events: bleeding/perforation rates, age increase, prep and sedation cardiopulmonary risks",
    "chunk_index": 22
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_23",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Adults ≥50: flexible sigmoidoscopy harms; follow-up colonoscopy complications; CT colonography radiation/overdiagnosis",
    "chunk_index": 23
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_16",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "gFOBT and FIT accuracy versus colonoscopy reference; age-related sensitivity/specificity",
    "chunk_index": 16
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_24",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Lifetime colonoscopy complications per 1000 screened ages 45–75 (CISNET model)",
    "chunk_index": 24
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_20",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "CISNET modeling: life‑years gained, colonoscopy harms, elevated‑risk cohort assumptions; high‑sensitivity gFOBT uncertainty",
    "chunk_index": 20
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_25",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Adults 45–49 CRC screening: USPSTF B, moderate net benefit; follow-up colonoscopy required",
    "chunk_index": 25
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_27",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Evidence gaps: Black adults disparities; sDNA‑FIT, CT colonography, serum/urine/capsule accuracy, mortality, long‑term outcomes",
    "chunk_index": 27
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_11",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Limited race‑specific screening accuracy/harms data; USPSTF endorses age‑45 start including Black adults",
    "chunk_index": 11
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_32",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal cancer epidemiology, early-onset trends, and guideline evidence citations",
    "chunk_index": 32
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_29",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "USPSTF membership, COI disclosures, honoraria/travel reimbursement, AHRQ support",
    "chunk_index": 29
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_31",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Copyright and reuse restrictions for USPSTF colorectal screening recommendations",
    "chunk_index": 31
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_28",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Guideline consensus: average‑risk colorectal cancer screening 50–75; initiation varies (45 in Black adults); 76–85 individualized",
    "chunk_index": 28
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_7",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 8",
    "chunk_index": 7
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_34",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Stool-based CRC screening: high-sensitivity gFOBT vs FIT/sDNA-FIT efficacy, harms, adherence, follow-up uncertainty",
    "chunk_index": 34
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_30",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "AHRQ funding role and USPSTF independence; clinical decision‑making caveats",
    "chunk_index": 30
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_26",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal screening: sDNA‑FIT interval 1–3 years; insufficient evidence to rank tests",
    "chunk_index": 26
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_39",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Adults ≥76: colonoscopy harms, CT colonography extracolonic findings; stool-test benefit–burden tradeoffs",
    "chunk_index": 39
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_0",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal cancer screening: adults 50–75 A; 45–49 B; 76–85 selective C",
    "chunk_index": 0
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_38",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal cancer screening benefits, test accuracy, and harms in adults 45–49",
    "chunk_index": 38
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_2",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Average-risk colorectal cancer screening modalities and intervals; selective 76–85",
    "chunk_index": 2
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_36",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Flexible sigmoidoscopy + FIT screening: mortality benefit, fewer complications, follow‑up colonoscopy harms, adherence",
    "chunk_index": 36
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_1",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "USPSTF age-stratified CRC screening recommendations: 50–75 A; 45–49 B; 76–85 C (average-risk adults)",
    "chunk_index": 1
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_40",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Modeling assumptions, test abbreviations, and uncertainties for stool-based CRC screening start age 45 vs 50",
    "chunk_index": 40
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_33",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 34",
    "chunk_index": 33
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_3",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal cancer screening net‑benefit: 50–75 substantial (high certainty); 45–49 moderate (moderate certainty)",
    "chunk_index": 3
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_9",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Screening intervals by test; no evidence supporting screening age 86+",
    "chunk_index": 9
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_37",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 38",
    "chunk_index": 37
  },
  {
    "chunk_id": "e294da8214d94d49bec9e1b83ccd698c_chunk_35",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 36",
    "chunk_index": 35
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_6",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Stool-based colorectal screening: FIT, gFOBT, sDNA-FIT methods, accuracy, annual testing, colonoscopy follow-up",
    "chunk_index": 6
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_12",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Equitable colorectal cancer screening in Black adults: systems, adherence, stool-based repeat testing",
    "chunk_index": 12
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_10",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "CRC disparities: screening/treatment access inequities drive higher Black mortality; rising incidence <50 in White/Hispanic",
    "chunk_index": 10
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_5",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Adults ≥45: age, racial/family risk; offer screening; exclude serum/urine/capsule tests",
    "chunk_index": 5
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_8",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "CRC screening age thresholds: rationale for starting at 45, rising <50 incidence, limited benefit >75",
    "chunk_index": 8
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_4",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 5",
    "chunk_index": 4
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_7",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 8",
    "chunk_index": 7
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_16",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "gFOBT and OC‑Sensor FIT accuracy for colorectal cancer and advanced adenomas; age-specific specificity",
    "chunk_index": 16
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_14",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal cancer screening update: adults 50–75 recommended; individualized 76–85; test accuracy and harms",
    "chunk_index": 14
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_13",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Stool-based vs direct-visualization CRC screening: colonoscopy follow-up, sample requirements and intervals",
    "chunk_index": 13
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_11",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 12",
    "chunk_index": 11
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_21",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Modeled benefits of CRC screening age 45–75 and serious colonoscopy harms per 10,000",
    "chunk_index": 21
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_23",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Harms of screening in adults: flexible sigmoidoscopy, follow‑up colonoscopy, CT colonography (radiation, extracolonic findings, overdetection)",
    "chunk_index": 23
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_22",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Screening colonoscopy harms — major bleeding/perforation per 10,000; age and bowel‑prep risks",
    "chunk_index": 22
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_24",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "CISNET-modeled lifetime colonoscopy complications for colorectal screening ages 45–75",
    "chunk_index": 24
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_19",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Prospective cohort: colonoscopy and biennial FIT lower colorectal cancer mortality (US, Taiwan)",
    "chunk_index": 19
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_27",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Research gaps: Black adults disparities; sDNA‑FIT mortality, CT colonography extracolonic harms, emerging tests",
    "chunk_index": 27
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_15",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 16",
    "chunk_index": 15
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_17",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 18",
    "chunk_index": 17
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_20",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "CISNET models: life‑years gained, colonoscopy burden, harms; elevated‑risk cohort focus; gFOBT uncertainty",
    "chunk_index": 20
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_28",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Organizational CRC screening age guidance: routine 50–75; 45 considered for Black adults; stop after 85",
    "chunk_index": 28
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_30",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Funder disclosure, AHRQ role, and independence of USPSTF CRC screening recommendations",
    "chunk_index": 30
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_31",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal cancer screening, USPSTF/AHRQ copyright, reuse and citation restrictions",
    "chunk_index": 31
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_25",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Adults 45–49 screening B recommendation; clarify colonoscopy follow‑up after abnormal tests",
    "chunk_index": 25
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_32",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal cancer incidence trends, early-onset rates, and cited evidence",
    "chunk_index": 32
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_18",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 19",
    "chunk_index": 18
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_36",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Flexible sigmoidoscopy+FIT screening: mortality benefit, modeling vs colonoscopy, follow‑up harms, availability, adherence",
    "chunk_index": 36
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_29",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "USPSTF membership, conflict-of-interest disclosures, AHRQ funding",
    "chunk_index": 29
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_38",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "CRC screening accuracy, benefits, and harms in adults 45–49",
    "chunk_index": 38
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_34",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Stool-based CRC screening: high-sensitivity gFOBT vs FIT/sDNA-FIT — efficacy, harms, adherence, interval efficiency",
    "chunk_index": 34
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_35",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "sDNA‑FIT home stool screening: colonoscopy follow-up harms and effectiveness trade‑offs",
    "chunk_index": 35
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_39",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Age ≥76 colorectal screening harms — increased colonoscopy serious adverse events, extracolonic CT findings; HSgFOBT less efficient",
    "chunk_index": 39
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_2",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Age-stratified pediatric Hodgkin lymphoma: histologic subtypes, EBV links, sex/socioeconomic patterns",
    "chunk_index": 2
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_3",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: age/sex patterns, EBV association, NLPHL prevalence",
    "chunk_index": 3
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_33",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Colorectal screening: annual high-sensitivity gFOBT — RCT mortality benefit, limited adenoma sensitivity, colonoscopy follow-up harms",
    "chunk_index": 33
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_40",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Modeling footnotes: per‑1000 outcomes (start age 45 vs 50); CISNET mean; HSgFOBT uncertainty; stool‑test efficiency tradeoffs",
    "chunk_index": 40
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_4",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Familial susceptibility in childhood Hodgkin lymphoma — sibling/sister excess, early-onset relative risk",
    "chunk_index": 4
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_5",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma germline susceptibility: twin risk, GWAS loci, familial variants",
    "chunk_index": 5
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_26",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 27",
    "chunk_index": 26
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_1",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric/adolescent Hodgkin lymphoma cure rates, prognostic factors for risk‑adapted therapy, age/sex incidence",
    "chunk_index": 1
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_0",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: high cure (90–95%), epidemiology, EBV/immunodeficiency links, shift to chemo+lower‑dose radiotherapy",
    "chunk_index": 0
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_8",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: transplant risk, painless cervical adenopathy, age‑varying mediastinal/B‑symptoms",
    "chunk_index": 8
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_10",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma prognostic factors: male sex, advanced stage, leukocytosis, anemia, B‑symptoms/bulky, race",
    "chunk_index": 10
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_12",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma epidemiology: perinatal, sibship, and familial/genetic risk factors",
    "chunk_index": 12
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_13",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric/adolescent Hodgkin lymphoma: tumor and serum EBV status predicting outcome",
    "chunk_index": 13
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_11",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma early FDG-PET response after 1–2 cycles predicts prognosis",
    "chunk_index": 11
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_7",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: EBV prevalence by age/geography and immunodeficiency–transplant risk",
    "chunk_index": 7
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_15",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin prognosis: CHIPS, baseline FDG‑PET metabolic tumor volume, CNS involvement, race",
    "chunk_index": 15
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_14",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin: risk from immunodeficiency, solid‑organ transplant, germline FAS mutations; pericardial effusion",
    "chunk_index": 14
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_9",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: stage IV extranodal prevalence and adverse pretreatment prognostic factors",
    "chunk_index": 9
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_17",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: HRS cell morphology and reactive infiltrate",
    "chunk_index": 17
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_16",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric/adolescent HL: chemo±low-dose nodal RT trials, interim FDG‑PET prognostication, racial survival",
    "chunk_index": 16
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_21",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL: male predominance, localized peripheral nonbulky lymphadenopathy, infrequent B symptoms",
    "chunk_index": 21
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_19",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric nodular‑sclerosing Hodgkin lymphoma: histology, TGF‑β fibrosis, HLA‑II risk haplotypes",
    "chunk_index": 19
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_20",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Mixed‑cellularity pediatric Hodgkin lymphoma: higher under‑10 incidence, EBV association, HRS‑rich histology, NHL mimic",
    "chunk_index": 20
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_22",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "NLPHL immunophenotype and diagnostic pitfalls in children — LP cells CD19/CD20, OCT2/BOB1; IgD correlations",
    "chunk_index": 22
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_37",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "ctx_header": "Medical content from Section 38",
    "chunk_index": 37
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_25",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Immunophenotype and B‑cell/CD20 prognostic markers in pediatric Hodgkin lymphoma",
    "chunk_index": 25
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_27",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric nodular lymphocyte‑predominant HL: EBV/IgD subsets, outcomes, microdissection/cfDNA genomic testing",
    "chunk_index": 27
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_30",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: JAK‑STAT genomic alterations (SOCS1, STAT6, JAK2; cfDNA prevalence)",
    "chunk_index": 30
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_26",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL and lymphocyte‑depleted HL: outcomes, immunophenotype, genetic analysis",
    "chunk_index": 26
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_18",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma immunophenotype: HRS CD30+/CD15±; NLPHL CD20+",
    "chunk_index": 18
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_28",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma genomics: 9p24 PD‑L1/PD‑L2 amplification driving immune‑evasion",
    "chunk_index": 28
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_29",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: CIITA fusions and B2M inactivation causing MHC class I/II loss; EBV differences",
    "chunk_index": 29
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_6",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 7",
    "chunk_index": 6
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_23",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "NLPHL LP‑cell B‑lineage immunophenotype and diagnostic mimics; variants affect EFS",
    "chunk_index": 23
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_24",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL: avoid radiation-alone in prepubescents; chemo±reduced-dose RT; late recurrences",
    "chunk_index": 24
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_37",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma staging—CBC, ESR, albumin; CT/MRI anatomy; PET functional imaging",
    "chunk_index": 37
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_33",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL genomics: LP cell B‑cell markers, IgD subtype, recurrent SOCS1/DUSP2/JUNB/SGK1 alterations",
    "chunk_index": 33
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_38",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: B-symptoms, nodal assessment, lab correlates, bulk implications for staging",
    "chunk_index": 38
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_36",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: Reed-Sternberg B‑cell origin and IgD+ NLPHL subset",
    "chunk_index": 36
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_31",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma JAK‑STAT and NF‑κB genomic alterations — 9p/JAK2, PTPN1, REL, EBV LMP1",
    "chunk_index": 31
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_40",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma CT/MRI nodal-involvement criteria: matting, visceral mass, and ≥15 mm single-dimension threshold",
    "chunk_index": 40
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_34",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric classical Hodgkin lymphoma: JAK‑STAT, CIITA fusions, PD‑L1/PD‑1 response biomarkers",
    "chunk_index": 34
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_42",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric 18F-FDG PET/CT: nodal-extranodal concordance, marrow detection accuracy, thymic/brown-fat pitfalls",
    "chunk_index": 42
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_41",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma staging: long-axis >2 cm abnormal; 1–2 cm PET-dependent; MRI vs PET-CT",
    "chunk_index": 41
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_47",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma risk stratification: stage, B‑symptoms, bulky disease; variable response criteria (size/PET)",
    "chunk_index": 47
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_35",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma genomics: 9p24.1, CIITA/A20 alterations, MHC/PD-L1, ctDNA prognostic",
    "chunk_index": 35
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_39",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL bulky criteria: mediastinal PA ratio ≥33% (US), CT ≥200 mL (EuroNet), peripheral >6 cm",
    "chunk_index": 39
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_46",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: preop steroids/low‑dose RT if airway compromise; Lugano staging guidance",
    "chunk_index": 46
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_51",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma response‑adapted therapy: interim PET/CT criteria (COG/EuroNet/GPOH)",
    "chunk_index": 51
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_44",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Biopsy technique and PET‑CT bone marrow staging in pediatric Hodgkin lymphoma",
    "chunk_index": 44
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_48",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma interim response–based risk stratification; new small CT lung nodules usually benign, require no further action",
    "chunk_index": 48
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_49",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric intermediate/advanced HL: response‑adapted dose‑dense ABVE‑PC + 21 Gy IFRT, 3 vs 5 cycles by rapid CT response",
    "chunk_index": 49
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_32",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 33",
    "chunk_index": 32
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_53",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma PET timing: chemo ≥3 weeks; postradiation 8–12 weeks",
    "chunk_index": 53
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_54",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma surveillance: limit routine CT; require pathologic confirmation before therapy change",
    "chunk_index": 54
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_55",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL imaging/prognostic biomarkers: FDG‑PET, baseline metabolic tumor volume, CRP, staging harmonization",
    "chunk_index": 55
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_50",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "CCG‑59704: pediatric IIB/IIIB(bulky)/IV Hodgkin response‑adapted BEACOPP with sex‑tailored consolidation, 5‑yr EFS 94%",
    "chunk_index": 50
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_59",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: FDG‑PET/CT staging, response prognosticity, surveillance CT impact on radiation",
    "chunk_index": 59
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_61",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: risk-adapted management—chemo, RT volume/dose/LD‑ISRT, NLPHL surgical cure",
    "chunk_index": 61
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_58",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Response‑adapted therapy trials and qPET interim FDG‑PET in pediatric classical Hodgkin lymphoma",
    "chunk_index": 58
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_52",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma complete response: 18F-FDG PET metabolic (Lugano/IWG 5-point)",
    "chunk_index": 52
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_62",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: restrict radiotherapy—lower dose/volume (15–25.5 Gy); NLPHL adolescents/young adults exception",
    "chunk_index": 62
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_56",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric FDG‑PET/CT: early response prognostic value and bone marrow assessment",
    "chunk_index": 56
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_57",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin staging: FDG‑PET/CT accuracy for marrow and biopsy utility",
    "chunk_index": 57
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_45",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 46",
    "chunk_index": 45
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_67",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma — risk-adapted combined chemotherapy plus LD‑ISRT improves EFS; OS unchanged",
    "chunk_index": 67
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_43",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 44",
    "chunk_index": 43
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_63",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin frontline multiagent chemotherapy: alkylator infertility/leukemia risk, ABVE‑PC/OEPA‑COPDAC",
    "chunk_index": 63
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_60",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Refer pediatric/adolescent Hodgkin lymphoma to multidisciplinary pediatric cancer centers; offer clinical trials",
    "chunk_index": 60
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_71",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL single-node IA/IIA: observation vs AV‑PC chemo ± low‑dose IFRT outcomes",
    "chunk_index": 71
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_72",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL: excellent EFS/OS with ABVE-PC (no IFRT); rituximab adult data, limited pediatric evidence",
    "chunk_index": 72
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_68",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma unfavorable features: B symptoms, bulk (mediastinal >=33%), extranodal, pleural effusion prognostic",
    "chunk_index": 68
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_66",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: chemotherapy-alone vs combined modality — resource-limited preference, higher alkylator/anthracycline toxicity",
    "chunk_index": 66
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_75",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: INRT vs ISRT prechemo PET positioning, ≥2 cm margins, proton dose-sparing evaluation",
    "chunk_index": 75
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_73",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "NLPHL in children: stage I favorable; rare DLBCL transformation; treatment-related mortality predominates",
    "chunk_index": 73
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_76",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma INRT/ISRT CT-simulation planning: pre/postchemo GTV/CTV and PET‑avid/bulky boost",
    "chunk_index": 76
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_77",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: organ-at-risk RT dose constraints and PET-guided postchemotherapy ISRT",
    "chunk_index": 77
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_70",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL de‑escalation trials: limited chemo/RT, brentuximab, checkpoint inhibitors; NLPHL surgery observation",
    "chunk_index": 70
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_65",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma chemo toxicity mitigation: ABVD limits, etoposide substitution, ABVE‑PC/OEPA‑COPDAC",
    "chunk_index": 65
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_74",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric high‑risk HL: central vs institutional iPET alters radiation decisions (89.7% concordance)",
    "chunk_index": 74
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_64",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 65",
    "chunk_index": 64
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_69",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: chemotherapy ± radiation, response‑adapted cycles; NLPHL resection exception; sex‑specific radiation limitation",
    "chunk_index": 69
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_81",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL IFRT: EFS benefit without OS gain; unnecessary after rapid CR; indicated for refractory/bulky relapse",
    "chunk_index": 81
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_82",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: modern lower RT doses vs historical IFRT breast-cancer risk; subgroup EFS uncertainty",
    "chunk_index": 82
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_84",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: response‑adapted ABVE/ABVE‑PC with IFRT (21–25.5 Gy) reduces chemotherapy exposure",
    "chunk_index": 84
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_83",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: procarbazine‑free dose‑dense regimens (ABVE‑PC, OEPA‑COPDAC); bleomycin replacements, etoposide, dexrazoxane",
    "chunk_index": 83
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_85",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL: ABVE‑PC response‑adapted dosing—3 vs 5 cycles with 21 Gy RT; dexrazoxane toxicity, low etoposide t‑AML risk",
    "chunk_index": 85
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_78",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma RT doses: 15–25 Gy baseline; 30–36 Gy for PET‑avid residuals; IMRT low‑dose bath concerns",
    "chunk_index": 78
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_79",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: proton and conformal RT, organ dose constraints, LD‑IFRT/ISRT to reduce chemotherapy toxicity",
    "chunk_index": 79
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_88",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "AHOD0031 pediatric intermediate-risk HL: ABVE‑PC early-response adaptation; IFRT vs observation, in-field relapse pattern",
    "chunk_index": 88
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_92",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL response-adapted PET after one cycle: IFRT (21 Gy) improves PFS for slow responders",
    "chunk_index": 92
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_89",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL rapid early response after 2 ABVE‑PC: IFRT vs no IFRT — similar EFS/OS",
    "chunk_index": 89
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_91",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric stage I–II nonbulky HL: COG AHOD0431 PET‑directed AV‑PC chemo, LD‑IFRT 21 Gy for non‑CR; salvage regimen & outcomes",
    "chunk_index": 91
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_87",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric favorable-risk Hodgkin lymphoma: VAMP ± limited-dose response-based IFRT outcomes; nonalkylating chemo lowers EFS in unfavorable",
    "chunk_index": 87
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_86",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric advanced HL COG‑59704 BEACOPP early‑intensification with sex‑tailored consolidation; IFRT omission in girls, high EFS but late toxicities",
    "chunk_index": 86
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_94",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric high‑risk Hodgkin lymphoma AHOD1331 phase III: Bv‑AVE‑PC vs ABVE‑PC improved 3‑yr EFS",
    "chunk_index": 94
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_80",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 81",
    "chunk_index": 80
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_93",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma slow early responders, relapses at initial site if IFRT omitted; PET after cycle1 prompts IFRT",
    "chunk_index": 93
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_96",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Phase III S1826: frontline nivolumab‑AVD superior to brentuximab‑AVD in advanced Hodgkin lymphoma (≥12)",
    "chunk_index": 96
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_101",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric early-stage classical HL: OEPA/AEPA ± CAPDAC chemo enabling radiation omission in responders",
    "chunk_index": 101
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_99",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL EuroNet‑PHL‑C1: OEPA responders RT omission; COPP vs COPDAC EFS and gonadotoxicity",
    "chunk_index": 99
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_90",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 91",
    "chunk_index": 90
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_97",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Advanced-stage adolescent Hodgkin lymphoma: S1826 phase III frontline nivolumab‑AVD superior PFS and tolerability",
    "chunk_index": 97
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_98",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: chemo-substitution impacts on EFS, gonadal toxicity, secondary leukemia, RT omission",
    "chunk_index": 98
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_103",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Adolescents/AYA Hodgkin lymphoma: adult ABVD ≥6 cycles (300 mg/m2); cardiomyopathy risk >250–300 mg/m2",
    "chunk_index": 103
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_105",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "AYA Hodgkin lymphoma: higher event risk than younger patients; trial disparities and mixed‑cellularity predict worse EFS",
    "chunk_index": 105
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_100",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Early-stage pediatric HL: COPP vs COPDAC EFS and gonadotoxicity; RT omission after adequate OEPA",
    "chunk_index": 100
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_102",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: risk-adapted, PET-guided chemo and limited-field radiation",
    "chunk_index": 102
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_107",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: chemo‑radiation regimens and late cardiac/second‑malignancy risks",
    "chunk_index": 107
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_110",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric nodular lymphocyte‑predominant HL: long-term outcomes, observation vs systemic therapy",
    "chunk_index": 110
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_104",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "AYAs (17–22) ECOG E2496 vs COG AHOD0031: 5‑yr FFS/OS differences, cohort imbalances",
    "chunk_index": 104
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_106",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Adolescent/young adult Hodgkin lymphoma prognosis: age and histology effects on 5‑yr EFS/OS",
    "chunk_index": 106
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_111",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Nodular lymphocyte‑predominant HL: transformation, outcomes, INRT/PET‑adapted radiotherapy",
    "chunk_index": 111
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_113",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric mediastinal Hodgkin lymphoma: proton vs IMRT/3DCRT dose reduction; response‑adapted and residual‑node RT outcomes",
    "chunk_index": 113
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_112",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma radiotherapy: involved-node/site field size, proton vs photon dosimetry, response-adapted use",
    "chunk_index": 112
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_114",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: high- and low-risk regimens, response‑adapted RT",
    "chunk_index": 114
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_95",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 96",
    "chunk_index": 95
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_117",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Children/adolescents refractory Hodgkin lymphoma: salvage therapies and prognosis for ≥12‑month relapses",
    "chunk_index": 117
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_116",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric/AYA Hodgkin: response‑adapted high‑risk chemo trials, regimen comparisons, long‑term cardiac morbidity data",
    "chunk_index": 116
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_115",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma trials: targeted/reduced radiotherapy, chemo regimens, QoL and late effects",
    "chunk_index": 115
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_119",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Brentuximab vedotin: adult FDA indications and response rates in post‑auto‑HSCT relapsed cHL",
    "chunk_index": 119
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_118",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Relapsed/refractory pediatric Hodgkin lymphoma: second-line chemo, checkpoint inhibitors, HSCT, ISRT, CD20-directed therapy",
    "chunk_index": 118
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_123",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric/adolescent relapsed/refractory Hodgkin lymphoma: brentuximab vedotin+bendamustine salvage outcomes; nivolumab activity",
    "chunk_index": 123
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_120",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Brentuximab vedotin for adults relapsed classical HL post‑autologous HSCT: FDA indications and phase II outcomes",
    "chunk_index": 120
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_109",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: chemo regimen comparisons, RT omission, nivolumab+AVD data",
    "chunk_index": 109
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_121",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory HL: brentuximab vedotin+gemcitabine, phase II dose 1.8 mg/kg; weight‑dependent PK",
    "chunk_index": 121
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_108",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 109",
    "chunk_index": 108
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_122",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 123",
    "chunk_index": 122
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_129",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Relapsed pediatric HL: timing+18F-FDG PET stratify RT vs HDC/auto‑HSCT; autologous preferred",
    "chunk_index": 129
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_131",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory Hodgkin lymphoma: autologous HSCT prognostic factors and consolidative ISRT indications",
    "chunk_index": 131
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_132",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Primary refractory pediatric Hodgkin lymphoma: salvage intensification, autologous HSCT outcomes and brentuximab responses",
    "chunk_index": 132
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_125",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 126",
    "chunk_index": 125
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_124",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 125",
    "chunk_index": 124
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_134",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory classical Hodgkin lymphoma — salvage, response‑adapted second‑line therapy and prognostic response",
    "chunk_index": 134
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_136",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed Hodgkin lymphoma salvage regimens and brentuximab vedotin outcomes",
    "chunk_index": 136
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_128",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory HL: PET‑guided IEP+ABVD reinduction risk‑adapted consolidation, may spare HSCT",
    "chunk_index": 128
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_139",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory Hodgkin lymphoma: autologous vs allogeneic SCT outcomes, high‑dose therapy",
    "chunk_index": 139
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_130",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma brentuximab vedotin consolidation post-autologous HSCT; BEAM/CBV conditioning, carmustine pulmonary toxicity",
    "chunk_index": 130
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_126",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 127",
    "chunk_index": 126
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_127",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 128",
    "chunk_index": 127
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_137",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric/AYA relapsed Hodgkin lymphoma: brentuximab vedotin combinations, PK, durability",
    "chunk_index": 137
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_144",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood HL: male gonadal toxicity — alkylators cause lasting azoospermia; non-alkylator regimens low risk",
    "chunk_index": 144
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_138",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Relapsed/refractory classical Hodgkin lymphoma—PD‑1 inhibitors after brentuximab vedotin and autologous SCT; pediatric/AYA evidence",
    "chunk_index": 138
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_145",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma ovarian toxicity: alkylating chemo and pelvic RT; ovarian transposition efficacy",
    "chunk_index": 145
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_133",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 134",
    "chunk_index": 133
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_141",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory Hodgkin lymphoma: autologous vs reduced‑intensity allogeneic HSCT outcomes",
    "chunk_index": 141
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_135",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 136",
    "chunk_index": 135
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_147",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin survivors: radiation dose-dependent thyroid dysfunction risk; higher in females, older age",
    "chunk_index": 147
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_149",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin survivors — elevated thyroid cancer risk; female, >25 Gy RT, >10y latency",
    "chunk_index": 149
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_140",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 141",
    "chunk_index": 140
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_143",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 144",
    "chunk_index": 143
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_142",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 143",
    "chunk_index": 142
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_152",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: anthracycline cardiotoxicity risk, dexrazoxane timing, 10–15 Gy heart dose goal",
    "chunk_index": 152
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_153",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma survivor subsequent neoplasm incidence linked to historic high‑dose RT/alkylators",
    "chunk_index": 153
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_146",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood HL survivors: premature ovarian failure risk with alkylating chemo + pelvic/abdominal radiation",
    "chunk_index": 146
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_151",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL radiation: late valve disease, CAD, cardiomyopathy; dose-volume–age dependence",
    "chunk_index": 151
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_154",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma survivors: chemo‑related myelodysplasia/AML risk; breast surveillance uncertain",
    "chunk_index": 154
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_159",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood HL survivors: breast cancer risk increases with chest RT (4–40 Gy); ovarian RT/alkylators lower risk",
    "chunk_index": 159
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_158",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Female childhood Hodgkin lymphoma survivors: radiation-associated breast cancer risk, cumulative incidence and latency",
    "chunk_index": 158
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_162",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma survivors — ovarian failure, premature menopause, fertility preservation, thyroid dysfunction",
    "chunk_index": 162
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_156",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Intermediate‑risk pediatric HL response‑adapted therapy: 10‑yr subsequent malignancy 1.3%, MDS/AML 0.2%",
    "chunk_index": 156
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_157",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin survivors — radiation-driven solid neoplasm risk; late breast cancer incidence and surveillance guidance",
    "chunk_index": 157
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_150",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 151",
    "chunk_index": 150
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_165",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Dexrazoxane‑associated secondary AML and second malignancy risk in pediatric Hodgkin survivors",
    "chunk_index": 165
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_148",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 149",
    "chunk_index": 148
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_164",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma late cardiac toxicity: surveillance, RT sparing, cardioprotection",
    "chunk_index": 164
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_166",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Long-term risk of secondary malignancies after childhood Hodgkin lymphoma: radiation dose and gender associations",
    "chunk_index": 166
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_167",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin survivors: secondary cancer risk by chemotherapy dose, radiation, dexrazoxane",
    "chunk_index": 167
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_161",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Dose-related testicular damage and androgen deficiency in male childhood Hodgkin lymphoma survivors",
    "chunk_index": 161
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_168",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Second malignancy risk after childhood Hodgkin therapy: chest radiation dose/volume, chemotherapy role, breast surveillance",
    "chunk_index": 168
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_163",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Late cardiovascular and thyroid neoplasm risk after pediatric Hodgkin lymphoma therapy",
    "chunk_index": 163
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_173",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "PDQ pediatric Hodgkin lymphoma — citation, copyright, image permissions, contact, reuse guidance",
    "chunk_index": 173
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_172",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "PDQ pediatric Hodgkin lymphoma lead reviewers and evidence‑ranking process",
    "chunk_index": 172
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_155",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 156",
    "chunk_index": 155
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_174",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: NCI content reuse, permissions, and syndication",
    "chunk_index": 174
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_170",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin update: extra‑axial CNS cases; BV improves frontline HRQoL; nivolumab+BV in low‑risk relapse",
    "chunk_index": 170
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_0",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: epidemiology, EBV/immunodeficiency links, shift to chemo with reduced-dose radiation",
    "chunk_index": 0
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_169",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Breast cancer risk and surveillance after chest radiotherapy/anthracyclines in childhood Hodgkin lymphoma survivors",
    "chunk_index": 169
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_4",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Familial Hodgkin lymphoma risk: higher in first‑degree relatives; siblings (esp. sisters) and early‑onset relatives",
    "chunk_index": 4
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_160",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 161",
    "chunk_index": 160
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_5",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma germline risk: twin data, GWAS loci (PAX5 GATA3 POLR1E IRF7)",
    "chunk_index": 5
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_9",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma prognosis — stage IV extranodal sites; B symptoms, anemia, hypoalbuminemia, male sex",
    "chunk_index": 9
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_1",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: cure rates, epidemiology, and prognostic factors guiding therapy",
    "chunk_index": 1
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_7",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: EBV prevalence, mixed-cellularity, prognostic and immunodeficiency risks",
    "chunk_index": 7
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_171",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed Hodgkin: EuroNet‑PHL‑R1 PET presalvage risk guide; steroid‑related osteonecrosis added",
    "chunk_index": 171
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_12",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma risk: family history, perinatal, birth-order, immune, genetic variants",
    "chunk_index": 12
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_2",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma age cohorts: sex, subtype distribution, EBV/SES links",
    "chunk_index": 2
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_6",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood HL familial germline variants (KDR, KLHDC8B, PAX5, GATA3, POLR1E, IRF7) associated with risk/EFS",
    "chunk_index": 6
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_10",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma prognostic factors (intermediate-risk): male, advanced stage, leukocytosis, anemia; racial disparities",
    "chunk_index": 10
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_13",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: EBV prevalence and prognostic value of serum EBV DNA",
    "chunk_index": 13
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_16",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: trials of chemo±low‑dose radiotherapy and interim FDG‑PET prognosis",
    "chunk_index": 16
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_3",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Children ≤14 Hodgkin lymphoma: subtype patterns, EBV association, family-size/socioeconomic risks",
    "chunk_index": 3
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_18",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma immunophenotype: HRS CD30+/CD45− vs NLPHL CD20+ popcorn cells",
    "chunk_index": 18
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_15",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Prognostic markers in pediatric Hodgkin lymphoma: CHIPS, FDG-PET metabolic tumor volume, race, CNS involvement",
    "chunk_index": 15
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_17",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma histology: HRS morphology and reactive microenvironment",
    "chunk_index": 17
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_19",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric nodular‑sclerosing Hodgkin lymphoma: age prevalence, TGF‑β fibrosis, lacunar cells, HLA class II haplotype risk",
    "chunk_index": 19
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_20",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric mixed-cellularity Hodgkin lymphoma: epidemiology, EBV positivity, histology diagnostic pitfalls",
    "chunk_index": 20
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_11",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma early PET response (after 1–2 cycles) predicts outcome, guides therapy",
    "chunk_index": 11
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_8",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Post–solid-organ transplant children: higher Hodgkin lymphoma risk; painless cervical nodes, adolescent mediastinal involvement",
    "chunk_index": 8
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_25",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Immunophenotypes and prognostic significance of CD20/B‑cell markers in pediatric Hodgkin lymphoma",
    "chunk_index": 25
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_14",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: immunodeficiency, transplant, familial Fas risks; pericardial effusion",
    "chunk_index": 14
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_26",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric lymphocyte‑predominant and lymphocyte‑depleted HL: outcomes, variant histology, immunophenotype/genetics",
    "chunk_index": 26
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_21",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL: 5–10% frequency, higher <10 yrs, male predominance, localized nonbulky peripheral nodes, rare B symptoms",
    "chunk_index": 21
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_28",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma immune‑evasion genomics: 9p24 PD‑L1/PD‑L2 gains, CIITA fusions",
    "chunk_index": 28
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_30",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: JAK‑STAT genomic alterations (SOCS1, STAT6, JAK2/9p; cfDNA)",
    "chunk_index": 30
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_24",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL: avoid RT alone prepubescent; chemo±RT with lower RT doses; late recurrences, treatment-related deaths",
    "chunk_index": 24
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_32",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: EBV LMP1-driven NF-kappaB; TNFAIP3/NFKB inhibitor loss; nonproductive Ig rearrangements",
    "chunk_index": 32
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_33",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood NLPHL genomics: LP B‑cell markers, IgD subtype, recurrent SOCS1/DUSP2/JUNB/SGK1 variants",
    "chunk_index": 33
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_27",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL genomics: EBV/IgD subsets, microdissection and cfDNA sequencing",
    "chunk_index": 27
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_31",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: 9p PD-L1/PD-L2/JAK2 gains; JAK‑STAT and NF‑κB pathway alterations",
    "chunk_index": 31
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_29",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma immune‑evasion: CIITA fusions, B2M inactivation, EBV correlation",
    "chunk_index": 29
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_37",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma staging labs and imaging: CBC/albumin/ESR, CT/MRI, PET",
    "chunk_index": 37
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_23",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL B‑cell immunophenotype, diagnostic mimics; histologic variants, IgD age/node associations",
    "chunk_index": 23
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_36",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HRS cell B‑cell derivation; NLPHL IgD‑positive L&H subset",
    "chunk_index": 36
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_34",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric classical Hodgkin lymphoma genomic drivers of immune evasion (JAK‑STAT, CIITA, PD‑L1)",
    "chunk_index": 34
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_41",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma nodal size thresholds and PET/MRI prognostic indices",
    "chunk_index": 41
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_35",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma genomic immune‑evasion (9p24.1, CIITA, β2M/MHC) and ctDNA prognostic biomarkers",
    "chunk_index": 35
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_38",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma B symptoms for staging/prognosis; nodal measurement and bulk criteria",
    "chunk_index": 38
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_42",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma 18F-FDG PET/CT: extranodal discordance, high marrow sensitivity, thymic/brown-fat false positives",
    "chunk_index": 42
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_45",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL staging: PET‑CT preferred; bone marrow biopsy only stage III/IV or B symptoms; anesthesia risks",
    "chunk_index": 45
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_43",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: Deauville PET criteria and biopsy tissue adequacy",
    "chunk_index": 43
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_48",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Interim response CT pulmonary nodules in pediatric Hodgkin lymphoma: common, usually benign, seldom predictive",
    "chunk_index": 48
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_22",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 23",
    "chunk_index": 22
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_47",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma risk stratification and protocol-specific early response criteria",
    "chunk_index": 47
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_49",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric intermediate/advanced Hodgkin lymphoma: response‑adapted dose‑dense ABVE‑PC with 21 Gy IFRT (3 vs 5 cycles by early response)",
    "chunk_index": 49
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_39",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma bulky disease criteria: mediastinal and peripheral definitions (US vs EuroNet vs Lugano)",
    "chunk_index": 39
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_52",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood HL complete response: 18F-FDG PET (Lugano 5-point), COG adoption; persistent mass permitted",
    "chunk_index": 52
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_40",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma CT/MRI nodal criteria: matting, visceral mass, ≥15 mm",
    "chunk_index": 40
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_53",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma response assessment: PET timing and CR definition (chemo ≥3wk; post-RT 8–12wk)",
    "chunk_index": 53
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_44",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma diagnostic biopsy choices and PET‑CT bone‑marrow staging sensitivity",
    "chunk_index": 44
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_54",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Intermediate/advanced pediatric Hodgkin lymphoma surveillance: reduce routine CT; biopsy-confirm relapses",
    "chunk_index": 54
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_50",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Response‑adapted dose‑intensive BEACOPP in pediatric advanced Hodgkin lymphoma; sex‑tailored consolidation",
    "chunk_index": 50
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_59",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: post-chemotherapy FDG-PET guiding omission of consolidation radiotherapy and CT surveillance",
    "chunk_index": 59
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_60",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: referral to pediatric multidisciplinary centers, clinical-trial enrollment",
    "chunk_index": 60
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_46",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: airway-compromise preop steroids/low‑dose RT; Lugano imaging staging; path confirmation for stage IV",
    "chunk_index": 46
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_55",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin imaging & biomarkers: PET/MTV prognosis and staging/response harmonization",
    "chunk_index": 55
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_58",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma response‑adapted COG trials and interim FDG‑PET (qPET) assessment",
    "chunk_index": 58
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_56",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "FDG‑PET early response and bone marrow staging in pediatric Hodgkin lymphoma",
    "chunk_index": 56
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_57",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma baseline PET/CT versus CT and bone marrow assessment accuracy",
    "chunk_index": 57
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_51",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL response‑adapted therapy: interim PET (Deauville>3) and CT ≥95% reduction guiding consolidation RT",
    "chunk_index": 51
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_62",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma — avoid single‑modality high‑dose RT; reduce RT dose/volume; rare NLPHL adolescent use",
    "chunk_index": 62
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_64",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: MOPP-associated infertility/leukemia; cyclophosphamide substitutions reduce risk",
    "chunk_index": 64
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_63",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL chemotherapy: MOPP toxicity, COPP substitutes, ABVE‑PC/OEPA‑COPDAC dose‑dense regimens",
    "chunk_index": 63
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_69",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: response‑adapted chemotherapy ± radiation; NLPHL surgery exception; sex‑based toxicity risks",
    "chunk_index": 69
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_67",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma — combined chemo+LD‑ISRT: improved EFS; risk‑adapted, response‑based treatment modifiers",
    "chunk_index": 67
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_70",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin trials: chemo/radiation de-escalation, brentuximab/checkpoint agents, surgery-first NLPHL observation",
    "chunk_index": 70
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_74",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric high‑risk Hodgkin lymphoma: central vs institutional interim 18F‑FDG PET/CT alters radiation allocation",
    "chunk_index": 74
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_71",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL favorable-stage: observation after single-node resection vs limited AV‑PC chemotherapy outcomes",
    "chunk_index": 71
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_75",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL radiation planning: INRT vs ISRT margins, prechemotherapy PET‑CT positioning, proton dose studies",
    "chunk_index": 75
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_61",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 62",
    "chunk_index": 61
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_77",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: OAR dose constraints and PET-guided postchemotherapy ISRT",
    "chunk_index": 77
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_66",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 67",
    "chunk_index": 66
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_72",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL: ABVE‑PC yields high CR/EFS, OS ~98%; pediatric rituximab data lacking",
    "chunk_index": 72
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_68",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 69",
    "chunk_index": 68
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_76",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma INRT/ISRT CT-simulation planning; GTV/CTV definitions and post-chemo PET-avid/bulky boost",
    "chunk_index": 76
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_65",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 66",
    "chunk_index": 65
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_81",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: adjuvant IFRT improves EFS, not OS; no AHOD0031 benefit in rapid responders; used for refractory/local control",
    "chunk_index": 81
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_79",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL radiotherapy: proton/IMRT, immobilization, organ constraints, LD‑IFRT/ISRT chemo-sparing",
    "chunk_index": 79
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_80",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma adjuvant radiotherapy: improves EFS, not OS; response‑stratified benefit and late‑effect mortality risk",
    "chunk_index": 80
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_73",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric NLPHL prognosis, transformation risk, involved-node radiation field reduction",
    "chunk_index": 73
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_84",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: response‑adapted ABVE/ABVE‑PC with IFRT 25.5 Gy after CR; chemo reduction in responders",
    "chunk_index": 84
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_78",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma RT dosing, PET‑avid escalation, boost practice, IMRT late‑effect concerns",
    "chunk_index": 78
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_88",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric intermediate‑risk Hodgkin lymphoma: AHOD0031 ABVE‑PC early‑response IFRT vs observation; relapses in irradiated/involved sites",
    "chunk_index": 88
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_82",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL: modern RT dose reduction vs historical IFRT breast‑cancer risk; subgroup EFS uncertainty",
    "chunk_index": 82
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_92",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL PET-defined early response: IFRT improves PFS for slow responders",
    "chunk_index": 92
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_89",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin early‑response ABVE‑PC trial: IFRT omission for CR — EFS/OS parity",
    "chunk_index": 89
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_90",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Stage I–II bulky/anemic HL: IFRT after ABVE‑PC improves EFS; DECA not significant in slow responders; relapses local",
    "chunk_index": 90
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_83",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL: procarbazine‑free dose‑dense regimens (ABVE‑PC, OEPA‑COPDAC); bleomycin replacements, dexrazoxane",
    "chunk_index": 83
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_93",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric slow early responders: relapses at initial site if IFRT omitted; PET equivocal/positive after one cycle triggered IFRT",
    "chunk_index": 93
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_86",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric advanced HL COG-59704: BEACOPP early intensification, sex‑tailored consolidation; infections, infertility, second neoplasms",
    "chunk_index": 86
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_97",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Adolescents/adults advanced Hodgkin: S1826 nivolumab‑AVD > brentuximab‑AVD 2‑yr PFS",
    "chunk_index": 97
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_85",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 86",
    "chunk_index": 85
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_99",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma—OEPA response: RT omission; COPDAC vs COPP gonadotoxicity",
    "chunk_index": 99
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_94",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric high‑risk classical Hodgkin lymphoma: Bv‑AVE‑PC vs ABVE‑PC (COG AHOD1331) 3‑yr EFS/relapse",
    "chunk_index": 94
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_95",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric high‑risk classical Hodgkin lymphoma: BV‑AVE‑PC reduces relapse, similar RT/toxicity, FDA approval",
    "chunk_index": 95
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_96",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "S1826 phase III: nivolumab‑AVD superior to brentuximab‑AVD in advanced HL (≥12 years)",
    "chunk_index": 96
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_87",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 88",
    "chunk_index": 87
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_104",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Ages 17–22 Hodgkin lymphoma outcomes: E2496 vs AHOD0031 — 5‑yr FFS/OS and confounders",
    "chunk_index": 104
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_101",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Early-stage pediatric classical HL: radiation omission after adequate OEPA/AEPA response — 5yr EFS/OS outcomes",
    "chunk_index": 101
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_91",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 92",
    "chunk_index": 91
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_108",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin: chemo ± low‑dose radiotherapy trials and late cardiac toxicity",
    "chunk_index": 108
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_107",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: chemo/radiation regimens and late second‑cancer, cardiac risks",
    "chunk_index": 107
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_98",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 99",
    "chunk_index": 98
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_106",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Adolescents vs younger children with Hodgkin lymphoma — 5‑yr EFS/OS; mixed‑cellularity worse",
    "chunk_index": 106
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_109",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: chemo regimen comparisons, RT omission, survivorship outcomes, nivolumab+AVD",
    "chunk_index": 109
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_103",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "AYA Hodgkin lymphoma — adult ABVD ≥6 cycles; anthracycline cardiotoxicity risk at 250–300 mg/m2",
    "chunk_index": 103
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_102",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Risk-adapted, response-based therapy criteria for pediatric Hodgkin lymphoma including early functional-imaging response",
    "chunk_index": 102
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_112",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: involved-node/site RT field size, response-adapted RT, proton dosimetry",
    "chunk_index": 112
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_113",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric mediastinal HL: proton vs 3DCRT/IMRT, response‑adapted and residual-node RT outcomes",
    "chunk_index": 113
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_100",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 101",
    "chunk_index": 100
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_111",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Nodular lymphocyte‑predominant HL: transformation/outcomes and PET‑adapted involved‑node RT",
    "chunk_index": 111
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_118",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory Hodgkin lymphoma salvage: chemo regimens, checkpoint inhibitors, HSCT, ISRT",
    "chunk_index": 118
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_117",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric refractory/recurrent Hodgkin lymphoma: salvage chemo, checkpoint inhibitors, autologous/allogeneic HSCT, ISRT",
    "chunk_index": 117
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_105",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 106",
    "chunk_index": 105
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_110",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric nodular lymphocyte‑predominant HL: outcomes; excision‑only watchful management; R‑CHOP in advanced",
    "chunk_index": 110
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_120",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Brentuximab vedotin for adults relapsed after autologous HSCT — FDA indications and phase II outcomes",
    "chunk_index": 120
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_114",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: risk-adapted chemotherapy regimens and early-response radiotherapy decisions",
    "chunk_index": 114
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_116",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric high‑risk Hodgkin lymphoma: chemo comparisons, response‑adapted therapy, cardiac late effects",
    "chunk_index": 116
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_122",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory HL: BV+gemcitabine (late‑toxicity‑sparing) and BV+bendamustine outcomes",
    "chunk_index": 122
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_115",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: reduced radiotherapy, chemo titration, QoL outcomes",
    "chunk_index": 115
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_125",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory HL: nivolumab+brentuximab vedotin induction 59% CMR; BV+bendamustine intensification → 94% pre‑HSCT",
    "chunk_index": 125
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_126",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory Hodgkin lymphoma: pembrolizumab 2 mg/kg q3w—60% ORR, significant high‑grade toxicities; FDA approval after ≥3 lines",
    "chunk_index": 126
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_129",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Relapsed pediatric Hodgkin lymphoma: PET‑adapted risk groups guiding RT vs autologous HSCT",
    "chunk_index": 129
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_119",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Brentuximab vedotin: adult post‑auto‑HSCT response rates, FDA indications relevant to pediatric recurrent HL",
    "chunk_index": 119
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_130",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric autologous HSCT: brentuximab vedotin consolidation/maintenance; BEAM/CBV (carmustine pulmonary risk)",
    "chunk_index": 130
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_132",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Primary‑refractory pediatric Hodgkin lymphoma salvage: HSCT outcomes and brentuximab vedotin response rates",
    "chunk_index": 132
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_123",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 124",
    "chunk_index": 123
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_134",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory classical Hodgkin lymphoma: risk‑ and response‑adapted salvage therapy guidelines",
    "chunk_index": 134
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_124",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 125",
    "chunk_index": 124
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_136",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Relapsed/refractory pediatric Hodgkin lymphoma: salvage chemotherapy and brentuximab outcomes",
    "chunk_index": 136
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_121",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 122",
    "chunk_index": 121
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_135",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory Hodgkin lymphoma salvage regimens and G-CSF dosing trials",
    "chunk_index": 135
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_137",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory Hodgkin lymphoma: brentuximab vedotin efficacy, PK, combo trials",
    "chunk_index": 137
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_127",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL: myeloablative chemo + autologous HSCT for refractory, ≤1‑yr relapse, or extensive recurrent disease after intensive therapy",
    "chunk_index": 127
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_138",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Relapsed/refractory pediatric/AYA Hodgkin lymphoma: PD‑1 inhibitors and salvage HSCT outcomes",
    "chunk_index": 138
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_140",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory HL: brentuximab vedotin consolidation post-autologous SCT; allo/auto transplant salvage",
    "chunk_index": 140
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_128",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory HL 18F-FDG PET–guided IEP+ABVD reinduction selecting RT vs autologous HSCT; identifies HSCT-avoidable patients with excellent PFS/OS",
    "chunk_index": 128
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_141",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Relapsed/refractory pediatric Hodgkin lymphoma: autologous and reduced‑intensity allogeneic HSCT outcomes",
    "chunk_index": 141
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_131",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory HL: autologous HSCT preparative regimens, prognostic factors, consolidative ISRT indications",
    "chunk_index": 131
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_139",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Relapsed/refractory pediatric Hodgkin lymphoma: autologous vs allogeneic HSCT, high-dose/PBSC salvage, EuroNet-PHL-R1",
    "chunk_index": 139
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_142",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Adolescent relapsed/refractory Hodgkin lymphoma: autologous HSCT, anti‑CD30 CAR‑T, CCSS survivorship risks",
    "chunk_index": 142
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_145",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma: ovarian toxicity risk with alkylating chemo and limited ovarian transposition benefit",
    "chunk_index": 145
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_150",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood/adolescent Hodgkin lymphoma survivors: elevated late cardiac morbidity and mortality; implications for long-term monitoring",
    "chunk_index": 150
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_149",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin survivors: ~18× thyroid cancer RR, ~1% absolute; dose>25 Gy, female, >10y",
    "chunk_index": 149
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_133",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 134",
    "chunk_index": 133
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_151",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL: late cardiac radiation effects — spectrum, dose–response, valve predominance",
    "chunk_index": 151
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_148",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin survivors — thyroid cancer risk after neck RT; dose >25 Gy, female, age <20, latency >10y",
    "chunk_index": 148
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_152",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric HL cardiac late effects: target mean heart dose 10–15 Gy; dexrazoxane cardioprotection",
    "chunk_index": 152
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_153",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Subsequent neoplasm incidence in pediatric HL survivors; historical high‑dose RT and alkylators",
    "chunk_index": 153
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_154",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin survivors: therapy‑related MDS/AML risk; breast surveillance shared decision",
    "chunk_index": 154
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_157",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin survivors — radiation-linked solid neoplasms (skin, breast, thyroid); high delayed breast cancer risk",
    "chunk_index": 157
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_158",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma survivors: radiation dose–dependent breast cancer risk, early onset/20–30y latency",
    "chunk_index": 158
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_143",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 144",
    "chunk_index": 143
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_156",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Intermediate‑risk childhood Hodgkin lymphoma (COG AHOD0031) 10‑yr subsequent malignancy and MDS/AML incidence",
    "chunk_index": 156
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_144",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 145",
    "chunk_index": 144
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_161",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Young male Hodgkin survivors: androgen deficiency, infertility risk, spermatogenesis recovery thresholds",
    "chunk_index": 161
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_147",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 148",
    "chunk_index": 147
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_146",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 147",
    "chunk_index": 146
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_164",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma — therapy-related cardiac late effects: imaging, RT planning, anthracycline cardioprotection",
    "chunk_index": 164
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_159",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Breast cancer risk in female childhood HL survivors: chest RT dose-dependent (4–40 Gy); ovarian irradiation/alkylating chemo lowers risk",
    "chunk_index": 159
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_165",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: dexrazoxane and secondary leukemia/second malignancy risk",
    "chunk_index": 165
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_168",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Secondary malignancy risk and breast-cancer surveillance after chest radiation in childhood HL survivors",
    "chunk_index": 168
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_169",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Secondary breast cancer risk and surveillance after childhood chest radiation and anthracyclines (female survivors)",
    "chunk_index": 169
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_162",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood HL survivorship: ovarian failure, fertility preservation and radiation‑induced thyroid disease",
    "chunk_index": 162
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_170",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma updates: extra‑axial CNS involvement; brentuximab vedotin QoL gains; nivolumab+BV salvage",
    "chunk_index": 170
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_172",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma: PDQ editorial reviewers, evidence grading, and content-use permissions",
    "chunk_index": 172
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_155",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 156",
    "chunk_index": 155
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_166",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin survivors: long-term secondary cancer risk by radiation dose and sex",
    "chunk_index": 166
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_174",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Childhood Hodgkin lymphoma content reuse, attribution, and digital syndication permissions",
    "chunk_index": 174
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_163",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin survivors: radiation and anthracycline‑related cardiac and thyroid late effects",
    "chunk_index": 163
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_1",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain management triage: assess psychosocial/substance modulators, benefit-versus-risk, opioid safety education",
    "chunk_index": 1
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_160",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 161",
    "chunk_index": 160
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_2",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Chronic cancer pain — longitudinal titration, opioid safety monitoring, core pain assessment",
    "chunk_index": 2
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_3",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Prevalence and multifactorial causes of cancer pain; younger patients at higher risk",
    "chunk_index": 3
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_167",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Medical content from Section 168",
    "chunk_index": 167
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_4",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Postoperative opioid overprescribing; persistent use risk after cancer surgery, higher with adjuvant chemotherapy",
    "chunk_index": 4
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_5",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "IV chemotherapy infusion pain syndromes and management (spasm, phlebitis, extravasation, mucositis, G‑CSF bone pain)",
    "chunk_index": 5
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_173",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric Hodgkin lymphoma PDQ citation, reuse permissions, update and contact info",
    "chunk_index": 173
  },
  {
    "chunk_id": "54d04f818d3746089361392d6498b545_chunk_171",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "ctx_header": "Pediatric relapsed/refractory HL: PET‑response–guided salvage therapy; glucocorticoid‑associated osteonecrosis added",
    "chunk_index": 171
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_9",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Prevalence, pathophysiology, anxiety/depression links, and opioid use patterns in cancer pain",
    "chunk_index": 9
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_10",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Postoperative opioid prescribing variability and risk factors for new persistent use",
    "chunk_index": 10
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_8",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain: depression risk, functional disability, posttreatment persistence, suicide and ED utilization",
    "chunk_index": 8
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_13",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Total pain in cancer: mechanisms (acute vs chronic) and somatization referral",
    "chunk_index": 13
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_0",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Characterize cancer pain: somatic/visceral/neuropathic, incidental/breakthrough, acute vs chronic to guide therapy",
    "chunk_index": 0
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_16",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer breakthrough pain: incident vs end-of-dose failure, 75% prevalence, episodic management issues",
    "chunk_index": 16
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_12",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Treatment-related pain syndromes: hand‑foot (palmar‑plantar) toxicity, interventions, and QoL impact",
    "chunk_index": 12
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_15",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer patients: psychosocial contributors, acute vs chronic pain mechanisms and management",
    "chunk_index": 15
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_14",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain mechanisms: nociceptive (somatic/visceral), neuropathic, plexopathy, allodynia, hyperalgesia",
    "chunk_index": 14
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_17",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer breakthrough pain — prevalence, characteristics, and single‑item intensity scales (NRS/VAS/categorical)",
    "chunk_index": 17
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_19",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Breast cancer CIPN: discordance between patient-reported and clinician-assessed pain influencing chemo dose decisions",
    "chunk_index": 19
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_20",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Initial cancer pain assessment: characterize pathophysiology, intensity, function; psychosocial/cultural screening",
    "chunk_index": 20
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_18",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain assessment: multidimensional instruments, PPG, research vs clinical practicality",
    "chunk_index": 18
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_22",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Psychosocial drivers of cancer pain assessment: catastrophizing, low self‑efficacy, chemical coping",
    "chunk_index": 22
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_21",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Comprehensive cancer pain assessment: goals, characteristics, treatment response including breakthrough, functional impact",
    "chunk_index": 21
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_6",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Prophylaxis for pegfilgrastim-induced bone pain: naproxen 500 mg BID x5–8d vs loratadine efficacy/safety",
    "chunk_index": 6
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_24",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "ECS‑CP and CPPS cancer pain risk scores; assessment limits in pediatric/cognitively impaired patients",
    "chunk_index": 24
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_23",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain assessment: substance use/chemical coping predicts higher opioid needs",
    "chunk_index": 23
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_26",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Racial/ethnic cultural influences on cancer pain communication, family support, and management",
    "chunk_index": 26
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_25",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Pain assessment in cognitively impaired/advanced dementia cancer patients: behavioral observation tools, caregiver report, cultural-spiritual context",
    "chunk_index": 25
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_29",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Advanced cancer pain: substance use, smoking-related opioid tapering, mood correlates, prognostic tools",
    "chunk_index": 29
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_28",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Catastrophizing, coping, and alcoholism screening affecting chronic cancer pain severity and opioid use",
    "chunk_index": 28
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_27",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain psychosocial and cultural influences; personalized pain-goal and patient-reported outcomes",
    "chunk_index": 27
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_7",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 8",
    "chunk_index": 7
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_34",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Acute cancer pain: start IR opioids, convert by 24‑hr MME; fentanyl options for breakthrough",
    "chunk_index": 34
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_30",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "ECS‑CP and behavioral pain scales for pediatric and cognitively impaired cancer patients",
    "chunk_index": 30
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_31",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain pharmacologic classes and adjuvants (acetaminophen, NSAIDs, opioids, neuropathic agents)",
    "chunk_index": 31
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_36",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Methadone for cancer pain: NMDA antagonism aids neuropathic/hyperalgesia; renal-safe, P‑gp/CYP drug-interaction risk",
    "chunk_index": 36
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_33",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid selection in cancer pain: weak/low‑dose strong for moderate; morphine preferred; oxycodone AE differences",
    "chunk_index": 33
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_37",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Methadone for cancer pain — QT prolongation risk; baseline and 2–4‑week ECG; monitor at 30–40 mg and 100 mg/day",
    "chunk_index": 37
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_39",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid adverse effects in cancer pain: sedation, cognitive/psychomotor impact, delirium, rotation, opioid‑induced hyperalgesia",
    "chunk_index": 39
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_11",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 12",
    "chunk_index": 11
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_41",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid respiratory depression: naloxone titration (methadone requires infusion); opioid-induced nausea: antiemetics, consider rotation",
    "chunk_index": 41
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_42",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid-induced nausea/vomiting: antiemetics, scopolamine; laxative titration goal one unforced bowel movement every 1–2 days",
    "chunk_index": 42
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_40",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid adverse effects in cancer patients: OIH recognition, rotation/methadone, respiratory depression risks",
    "chunk_index": 40
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_46",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Hydromorphone safety and opioid rotation for renal/hepatic failure",
    "chunk_index": 46
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_44",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid-induced endocrinopathy: HRT contraindications; immunomodulation and hepatic/CYP metabolism cautions",
    "chunk_index": 44
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_48",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Patient-level barriers to opioid use in cancer: addiction, side-effect, progression fears",
    "chunk_index": 48
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_47",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid rotation for cancer pain: uncontrolled pain or OIN, selection factors, outpatient outcomes",
    "chunk_index": 47
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_49",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Physician opioid-prescribing barriers; CDC chronic-pain guideline reduced oncologist prescriptions and increased ED visits among Medicare cancer patients",
    "chunk_index": 49
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_50",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Pediatric cancer survivors: greater post-CDC guideline reductions in opioid prescribing and misuse indicators",
    "chunk_index": 50
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_32",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 33",
    "chunk_index": 32
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_53",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid initiation in cancer patients after acute events: addiction risk assessment and differential diagnoses",
    "chunk_index": 53
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_35",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 36",
    "chunk_index": 35
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_54",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid misuse signs in cancer patients and criteria for highly structured opioid therapy",
    "chunk_index": 54
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_55",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid risk mitigation in cancer pain: agreements, prescription monitoring, urine drug testing, deterrent formulations",
    "chunk_index": 55
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_38",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 39",
    "chunk_index": 38
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_43",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 44",
    "chunk_index": 43
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_57",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "SNRIs and TCAs for cancer neuropathic pain: dosing, cautions, anticholinergic risks",
    "chunk_index": 57
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_51",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Racial disparities in opioid prescribing and REMS/PDMP barriers among Medicare decedents >65 with advanced cancer",
    "chunk_index": 51
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_52",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid misuse and overdose risk in cancer patients; elevated early overdose in colorectal survivors",
    "chunk_index": 52
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_62",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain pharmacotherapy: strong opioid comparisons, adjunct NSAID/acetaminophen, adherence",
    "chunk_index": 62
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_45",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 46",
    "chunk_index": 45
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_64",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid strategies for cancer pain: rapid‑onset agents, fentanyl formulations, tapentadol, methadone conversion/safety",
    "chunk_index": 64
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_58",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Dexamethasone‑preferred corticosteroid adjuvant for bone/neuropathic/obstructive cancer pain: dosing, taper, interactions",
    "chunk_index": 58
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_59",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Bisphosphonates for metastatic bone pain — adjunctive therapy, RT alternative, acute‑phase reactions",
    "chunk_index": 59
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_65",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid-induced adverse-effect management in cancer patients: nausea, constipation, hyperalgesia; methylphenidate adjuncts",
    "chunk_index": 65
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_66",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid adverse effects in cancer/palliative care: cognitive dysfunction, delirium, hyperalgesia, respiratory depression risk/management",
    "chunk_index": 66
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_61",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Clinical trial evidence for opioids, NSAIDs, acetaminophen, adjuvant analgesics in cancer pain",
    "chunk_index": 61
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_69",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain opioid-rotation best practices; renal impairment dosing and oncology prescribing trends",
    "chunk_index": 69
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_68",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid adverse effects & management: OIC, endocrine, renal dosing, immunologic",
    "chunk_index": 68
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_60",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Denosumab vs zoledronic acid for bone-metastasis pain: efficacy, hypocalcemia risk in renal impairment",
    "chunk_index": 60
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_56",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 57",
    "chunk_index": 56
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_73",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Adjuvant analgesics in advanced cancer: corticosteroids and zoledronic acid for bone pain",
    "chunk_index": 73
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_74",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Zoledronic acid and denosumab for metastatic bone pain: efficacy and ONJ risk",
    "chunk_index": 74
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_71",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid misuse risk, chemical coping, and long‑term opioid management in cancer patients/survivors",
    "chunk_index": 71
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_72",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Risk mitigation (urine testing, renewal clinics) plus opioid adjuncts for cancer pain",
    "chunk_index": 72
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_63",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Transdermal and extended‑release opioids for cancer pain: rotation/equianalgesic issues, hospice/cachectic patients",
    "chunk_index": 63
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_77",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Interventional analgesia for refractory cancer pain: intrathecal pumps, epidural catheters, cordotomy",
    "chunk_index": 77
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_70",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Age-stratified opioid prescribing trends, access disparities, and OUD in cancer patients",
    "chunk_index": 70
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_75",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Interventional procedures for refractory cancer pain: nerve blocks, neuroaxial, cordotomy",
    "chunk_index": 75
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_81",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Palliative bone metastasis re-irradiation: timing, response rates, dexamethasone prophylaxis",
    "chunk_index": 81
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_84",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Neural blockade and neurosurgical interventions for refractory cancer pain",
    "chunk_index": 84
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_78",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Interdisciplinary palliative/supportive care referral for refractory cancer pain and QOL benefits",
    "chunk_index": 78
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_83",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Phase III radium‑223 in symptomatic castration‑resistant prostate cancer: delays skeletal events, improves survival",
    "chunk_index": 83
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_85",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Pain palliation predictors: radiotherapy, cordotomy, palliative‑care referral",
    "chunk_index": 85
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_86",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Metastatic bone pain palliative radiotherapy: single‑fraction vs multiple‑fraction efficacy and retreatment",
    "chunk_index": 86
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_87",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Palliative bone metastasis pain: radiotherapy effects, dexamethasone flare prophylaxis, samarium-153 trials",
    "chunk_index": 87
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_90",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Visceral vs neuropathic cancer pain: localization, sensitization, opioid response, nonopioid therapy evidence",
    "chunk_index": 90
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_89",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Bone metastasis pain — pathophysiology, incident pain, opioid therapy, orthopedic evaluation",
    "chunk_index": 89
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_67",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 68",
    "chunk_index": 67
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_76",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 77",
    "chunk_index": 76
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_80",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 81",
    "chunk_index": 80
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_91",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer neuropathic pain: gabapentin/pregabalin first-line or adjunct; superior vs fentanyl/TCAs, rapid benefit",
    "chunk_index": 91
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_79",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 80",
    "chunk_index": 79
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_95",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Breast cancer CIPN 24‑month prevalence, QOL impact, docetaxel regimens, risk factors",
    "chunk_index": 95
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_82",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 83",
    "chunk_index": 82
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_98",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "CIPN: scrambler therapy RCTs vs guideline therapy show marked VAS reduction; no sham control",
    "chunk_index": 98
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_88",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 89",
    "chunk_index": 88
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_94",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Neurotoxic cancer therapies causing CIPN: agents, prevalence, persistent symptoms",
    "chunk_index": 94
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_101",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Geriatric cancer pain: altered PK/PD, start‑low dosing, polypharmacy and functional risks",
    "chunk_index": 101
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_92",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer neuropathic pain: gabapentin/pregabalin first-line vs TCA/SNRI efficacy caveats",
    "chunk_index": 92
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_99",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Chemotherapy-induced peripheral neuropathy: scrambler therapy RCT vs TENS — higher responder rate",
    "chunk_index": 99
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_102",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Geriatric cancer patients with musculoskeletal pain: prefer acetaminophen ≤3g/day (2g if hepatotoxic risk); NSAID precautions",
    "chunk_index": 102
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_104",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Assessment and adjuvant analgesics for bone‑metastasis and neuropathic cancer pain",
    "chunk_index": 104
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_103",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Geriatric cancer pain: lower opioid doses, higher sedation/constipation risk; avoid TCAs, use duloxetine, gabapentin, topical agents",
    "chunk_index": 103
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_97",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Oxaliplatin CIPN risk factors; gabapentin ineffective; limited TCA/topical evidence",
    "chunk_index": 97
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_106",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Postmastectomy/post‑thoracotomy persistent pain: IV lidocaine, paravertebral block, TENS trials",
    "chunk_index": 106
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_93",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 94",
    "chunk_index": 93
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_96",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Breast cancer CIPN: long-term risk factors, African‑American genetic risk, duloxetine's marginal pain benefit",
    "chunk_index": 96
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_111",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Geriatric cancer pain: analgesic pharmacology, hepatic impairment, high‑risk medications",
    "chunk_index": 111
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_112",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "PDQ cancer pain: editorial independence, monthly literature review and update criteria",
    "chunk_index": 112
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_113",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "PDQ Cancer Pain editorial process: lead reviewers, evidence levels, public comments, citation format",
    "chunk_index": 113
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_110",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Procedural sedation; post‑lumbar puncture headache; geriatric pain pharmacotherapy",
    "chunk_index": 110
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_0",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF final recommendation: biennial mammography for women starting at age 40",
    "chunk_index": 0
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_114",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain PDQ image permissions, attribution, syndication, and reimbursement disclaimer",
    "chunk_index": 114
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_108",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Chemotherapy-induced peripheral neuropathy: risk factors, GWAS, racial disparities, nortriptyline trial (taxane/platinum)",
    "chunk_index": 108
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_100",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 101",
    "chunk_index": 100
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_1",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer biennial screening 40–74 (B grade): research gaps — disparities, dense breasts, older women",
    "chunk_index": 1
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_2",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Biennial mammography for all women age 40–74; research gaps (disparities, dense breasts, older women)",
    "chunk_index": 2
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_107",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Prevention trials for post‑thoracotomy pain and chemo‑induced peripheral neuropathy",
    "chunk_index": 107
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_7",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer screening clinician tools, evidence reviews, and research gaps",
    "chunk_index": 7
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_4",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Women 40–74: biennial mammography recommendation (USPSTF Grade B); 75+ insufficient evidence",
    "chunk_index": 4
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_105",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 106",
    "chunk_index": 105
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_5",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Biennial mammography for cisgender women and AFAB persons 40–74 (Grade B); ≥75 evidence insufficient (I)",
    "chunk_index": 5
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_9",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "US breast cancer epidemiology: deaths, rising 40–49 incidence, NH White/Black stage disparities",
    "chunk_index": 9
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_3",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Dense breasts: reduced mammogram sensitivity; supplemental ultrasound/MRI evidence insufficient; biennial screening from 40, research needed",
    "chunk_index": 3
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_13",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Black women — elevated breast cancer mortality; social determinants, segregation, triple‑negative risk",
    "chunk_index": 13
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_11",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "DBT with digital/synthetic mammography: detection, PPV, and biennial vs annual tradeoffs",
    "chunk_index": 11
  },
  {
    "chunk_id": "6824e243e219421394b3ceb128b1ea23_chunk_109",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 110",
    "chunk_index": 109
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_14",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Black women: higher triple‑negative incidence, social determinants and follow‑up delays",
    "chunk_index": 14
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_16",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Dense-breasted women: insufficient evidence supplemental ultrasound/MRI after normal mammogram improves outcomes",
    "chunk_index": 16
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_15",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Racial/ethnic disparities in follow-up and endocrine‑therapy adherence; screening mammography ≥75 yrs uncertain",
    "chunk_index": 15
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_12",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Screen-detected DCIS: overdiagnosis uncertainty, variable management and outcome disparities",
    "chunk_index": 12
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_8",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer screening: USPSTF recommendation framework—benefit‑harm balance, no cost consideration, equity & individualized decisions",
    "chunk_index": 8
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_19",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "CISNET models evaluating screening benefits/harms by age, modality, interval; Black‑specific models",
    "chunk_index": 19
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_21",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Mammography cessation vs continuation in women 70–84: mortality benefit 70–74 only",
    "chunk_index": 21
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_18",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Women’s mammography-based screening strategies review: age/interval/modality, stage-shift criteria, evidence gaps",
    "chunk_index": 18
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_6",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Medical content from Section 7",
    "chunk_index": 6
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_17",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF update: biennial mammography 40–74; DBT/digital efficacy; gaps—dense-breast supplemental, ≥75",
    "chunk_index": 17
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_20",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Mammography RCTs: age-stratified breast cancer mortality reductions; no all-cause mortality benefit, limited Black enrollment",
    "chunk_index": 20
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_25",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Biennial mammography (40–74): DBT ≈ digital; MRI/ultrasound unstudied; ~1376 false‑positives/1000",
    "chunk_index": 25
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_24",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Modeling: biennial screening favored for life‑years, including Black women; DBT vs digital lacks mortality RCTs",
    "chunk_index": 24
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_23",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer, ages 40–49: annual vs triennial mammography—similar mortality and tumor features",
    "chunk_index": 23
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_10",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Medical content from Section 11",
    "chunk_index": 10
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_28",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Interval between mammograms: interval cancer rates, false-positives, overdiagnosis; racial differences",
    "chunk_index": 28
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_29",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Interval cancer risk with DBT versus digital mammography screening — RCTs show no significant difference",
    "chunk_index": 29
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_30",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Women 40–74 screening: DBT vs digital mammography — 10‑yr false‑positive and biopsy risk, DCIS detection",
    "chunk_index": 30
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_31",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "DBT vs digital mammography: doubled radiation; MRI adjunct in extremely dense breasts lowers interval cancers but raises extramammary cascades",
    "chunk_index": 31
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_34",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Screening interval: biennial vs annual mammography — models favor biennial",
    "chunk_index": 34
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_26",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer screening overdiagnosis — biennial 40–74 model estimates ≈14/1000 (4–37 range)",
    "chunk_index": 26
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_37",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF rationale for B biennial mammography (ages 40–74): modeling, benefits vs harms",
    "chunk_index": 37
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_22",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Modeling of biennial mammography starting at 40 vs 50 — additional deaths averted, life‑years gained (greater for Black women)",
    "chunk_index": 22
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_39",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF breast cancer screening authors, COI recusals, and JAMA citation",
    "chunk_index": 39
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_33",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Age‑limit evidence: no benefit ages 75+; no data for <40 or risk‑based screening",
    "chunk_index": 33
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_36",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast screening disparities in Black women: treatment timeliness, biomarker risks, research",
    "chunk_index": 36
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_41",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer screening — funder involvement, USPSTF independence, copyright/reuse limits",
    "chunk_index": 41
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_40",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF breast cancer screening: COI, funding, AHRQ role, honoraria",
    "chunk_index": 40
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_43",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Female breast cancer epidemiology sources: SEER age/race incidence and professional guidance",
    "chunk_index": 43
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_42",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Copyright and redistribution restrictions plus citation requirement for USPSTF screening statement",
    "chunk_index": 42
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_46",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Evidence gaps in breast cancer screening: DCIS prognosis, Black women equity",
    "chunk_index": 46
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_47",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Research gaps: supplemental screening for dense breasts; Black women disparities; DCIS prognosis",
    "chunk_index": 47
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_27",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Medical content from Section 28",
    "chunk_index": 27
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_32",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Age 40–49: digital mammography plus ultrasound — similar interval cancer, doubled biopsy/false‑positive rates",
    "chunk_index": 32
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_44",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Biennial mammography screening: moderate net benefit ages 40–74; insufficient evidence for 75+ and supplemental ultrasound/MRI",
    "chunk_index": 44
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_2",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain longitudinal monitoring and opioid management: assessment, titration, equianalgesic dosing, adverse effects",
    "chunk_index": 2
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_3",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Epidemiology and causes of cancer pain: tumor, treatment, comorbidity; higher risk in younger patients",
    "chunk_index": 3
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_35",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Medical content from Section 36",
    "chunk_index": 35
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_5",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "IV chemotherapy infusion pain syndromes and pegfilgrastim bone‑pain prophylaxis trials",
    "chunk_index": 5
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_1",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain treatment decisions: assess multifactorial contributors, risk–benefit, referrals, opioid safety counseling",
    "chunk_index": 1
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_6",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Pegfilgrastim-induced bone pain prevention: naproxen vs loratadine, phase II/III RCTs",
    "chunk_index": 6
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_8",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain: depression risk, work disability, persistent survivorship pain, suicidality, ED admissions",
    "chunk_index": 8
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_38",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Medical content from Section 39",
    "chunk_index": 38
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_9",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain prevalence and anxiety/depression correlates; postoperative opioid use patterns",
    "chunk_index": 9
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_0",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain causes and characterization: somatic, visceral, neuropathic; incidental/breakthrough; treatment-related",
    "chunk_index": 0
  },
  {
    "chunk_id": "d7656e488ac94b29b3259773bac09838_chunk_45",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Biennial mammography outcomes; insufficient evidence for screening ≥75 and supplemental ultrasound/MRI after negative mammogram",
    "chunk_index": 45
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_13",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer total pain: psychosocial drivers, mechanisms, somatization referral",
    "chunk_index": 13
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_7",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Treatment-related skin and neuropathic pain (EGFR rash, hand‑foot, postherpetic); dose reduction, dexamethasone prevents radiation pain flares",
    "chunk_index": 7
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_14",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain classification: nociceptive (somatic/visceral), neuropathic, allodynia, hyperalgesia, plexopathy",
    "chunk_index": 14
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_10",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Postoperative opioid prescribing variability, new persistent use risk, and reduction interventions in surgical patients",
    "chunk_index": 10
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_16",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Breakthrough pain in cancer: incidence, incident pain, end‑of‑dose flares",
    "chunk_index": 16
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_17",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer breakthrough pain characteristics and intensity scales (NRS, VAS, categorical)",
    "chunk_index": 17
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_15",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain classification: acute vs chronic mechanisms, psychosocial contributors, multidisciplinary care",
    "chunk_index": 15
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_21",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain assessment: goals, history, intensity, radiation, treatment response, breakthrough, function, physical exam",
    "chunk_index": 21
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_19",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "CIPN assessment discordance in breast cancer: patient-reported symptoms drive treatment changes",
    "chunk_index": 19
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_18",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain assessment: multidimensional instruments, PPG, pediatric/cognitive adaptations",
    "chunk_index": 18
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_22",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Psychosocial drivers of cancer pain: depression, catastrophizing, low self‑efficacy, chemical coping",
    "chunk_index": 22
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_24",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain risk scores: ECS‑CP domains and CPPS predictors",
    "chunk_index": 24
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_20",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Comprehensive assessment of cancer pain: pathophysiology, intensity, function, psychosocial/cultural drivers",
    "chunk_index": 20
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_25",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Nonverbal or cognitively impaired patients: observational pain assessment, caregiver report, cultural/spiritual context",
    "chunk_index": 25
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_4",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 5",
    "chunk_index": 4
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_28",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Catastrophizing and substance-use screening predict worse cancer pain and higher opioid use",
    "chunk_index": 28
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_26",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Ethnic and cultural effects on cancer pain communication and family-centered management",
    "chunk_index": 26
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_27",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Personalized pain goals, psychosocial factors, and cultural differences in cancer pain assessment",
    "chunk_index": 27
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_30",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain assessment tools (ECS‑CP, Faces, PACSLAC) for pediatric and cognitively impaired",
    "chunk_index": 30
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_31",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain pharmacologic agents and pediatric pain scales",
    "chunk_index": 31
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_33",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Moderate–severe cancer pain: opioid choice — morphine favored; oxycodone comparable",
    "chunk_index": 33
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_12",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Hand–foot (palmar‑plantar) erythrodysesthesia from chemo/targeted agents: prevention and management trials",
    "chunk_index": 12
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_23",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain assessment—substance use, chemical coping, nicotine effects on opioid dosing",
    "chunk_index": 23
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_35",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Rapid-onset fentanyl in opioid‑tolerant cancer patients: product‑specific titration, not interchangeable; FDA REMS required; methadone needs expert prescribing",
    "chunk_index": 35
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_11",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 12",
    "chunk_index": 11
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_39",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain opioid adverse‑effect management: sedation mitigation, rotation, assess delirium and opioid‑induced hyperalgesia",
    "chunk_index": 39
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_29",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Advanced cancer: smoking/alcohol and anxiety/depression affect analgesic use; prognostic/Edmonton scales",
    "chunk_index": 29
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_32",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Acetaminophen/NSAIDs as opioid-sparing adjuncts in cancer pain; caution in elderly and renal/hepatic/cardiac disease",
    "chunk_index": 32
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_42",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid-induced nausea/vomiting treatments and laxative titration in cancer patients",
    "chunk_index": 42
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_44",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid-induced endocrine dysfunction: HRT contraindications, CYP metabolism, hepatic impairment caution",
    "chunk_index": 44
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_38",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid-induced neurotoxicity in advanced cancer: delirium/myoclonus, risk factors, management",
    "chunk_index": 38
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_36",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Methadone for cancer pain: NMDA antagonist benefits, renal-sparing profile, and DDIs",
    "chunk_index": 36
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_41",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid respiratory depression (incl. methadone) and OINV management — naloxone (infusion/nasal), antiemetics, rotation",
    "chunk_index": 41
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_45",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer patients: opioid PK and dose cautions in hepatic disease or CKD",
    "chunk_index": 45
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_47",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain opioid rotation: indications, OIN, selection factors, outpatient success",
    "chunk_index": 47
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_34",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 35",
    "chunk_index": 34
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_49",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "CDC noncancer opioid guideline spillover reducing oncologist prescriptions; end-of-life ED visits rise",
    "chunk_index": 49
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_48",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Patient-level opioid barriers in cancer: addiction, side effects, disease-progression fears",
    "chunk_index": 48
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_50",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Pediatric cancer survivors: CDC guideline decreased opioid prescribing and misuse vs peers",
    "chunk_index": 50
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_37",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 38",
    "chunk_index": 37
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_51",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Racial disparities: Black/Hispanic undertreatment and urine screening in opioid prescribing for older poor‑prognosis cancer patients",
    "chunk_index": 51
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_40",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 41",
    "chunk_index": 40
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_54",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer patients: aberrant opioid-use behaviors; risk stratification and structured therapy (frequent visits, pill limits, UDT)",
    "chunk_index": 54
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_55",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid risk mitigation in cancer patients: agreements, PDMP, random urine testing, abuse‑deterrent formulations",
    "chunk_index": 55
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_59",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Bisphosphonates for metastatic bone pain: adjunct to analgesics/RT, efficacy and acute‑phase adverse effects",
    "chunk_index": 59
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_53",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer patients on opioids: assess addiction risk; distinguish addiction vs tolerance/aberrant behavior",
    "chunk_index": 53
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_43",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 44",
    "chunk_index": 43
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_62",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Advanced cancer pain: strong opioid comparisons, low‑dose morphine trials, NSAID/paracetamol adjuncts, adherence",
    "chunk_index": 62
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_56",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer neuropathic pain—gabapentin/pregabalin mechanism, titration, adverse effects",
    "chunk_index": 56
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_61",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Nonopioid and adjuvant analgesics in cancer pain — trials and evidence",
    "chunk_index": 61
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_60",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Denosumab for bone‑metastasis pain: longer time to pain worsening, less nephrotoxicity, hypocalcemia risk if CrCl<30",
    "chunk_index": 60
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_65",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer opioid adverse-effect management: nausea, bowel dysfunction, hyperalgesia, toxicity",
    "chunk_index": 65
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_64",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid options for cancer pain: tapentadol, rapid‑onset fentanyl for breakthrough pain, methadone conversion/safety",
    "chunk_index": 64
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_46",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 47",
    "chunk_index": 46
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_69",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid-rotation strategies, renal-dysfunction dosing, and oncologist prescribing trends",
    "chunk_index": 69
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_68",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid adverse effects and management: OIC, androgen deficiency, immunologic issues, renal dosing",
    "chunk_index": 68
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_52",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 53",
    "chunk_index": 52
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_70",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid prescribing trends, access disparities, and misuse/OUD risk in cancer patients (EOL, pediatric survivors, older adults)",
    "chunk_index": 70
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_63",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Transdermal and extended‑release opioids for cancer pain: efficacy, rotation, equianalgesic ratios (hospice/cachexia)",
    "chunk_index": 63
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_72",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid risk mitigation and monitoring (renewal clinics, urine testing) for cancer pain",
    "chunk_index": 72
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_74",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Bone-modifying agents for cancer bone metastasis pain: efficacy, dosing, ONJ risk",
    "chunk_index": 74
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_57",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 58",
    "chunk_index": 57
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_75",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Interventional management for refractory cancer pain: nerve blocks, neuroaxial analgesia, cordotomy",
    "chunk_index": 75
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_71",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Opioid therapy in cancer: persistent use, misuse predictors, chemical coping",
    "chunk_index": 71
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_58",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 59",
    "chunk_index": 58
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_80",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Nonspine bone metastases: single‑fraction high‑dose SBRT (12–16 Gy) improved pain and 1–2‑yr survival (phase II)",
    "chunk_index": 80
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_81",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Re-irradiation for painful bone metastases: timing, response rates, dexamethasone for flare prophylaxis",
    "chunk_index": 81
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_73",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Corticosteroids and zoledronic acid for adjuvant pain control in advanced cancer",
    "chunk_index": 73
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_66",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer patients: opioid neurocognitive effects, terminal delirium, hyperalgesia, respiratory depression risk",
    "chunk_index": 66
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_78",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Referral to interdisciplinary palliative/supportive care for refractory cancer pain; early integration improves QOL",
    "chunk_index": 78
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_67",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 68",
    "chunk_index": 67
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_84",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer-related refractory pain: interventional analgesia — neural blockade, neuraxial, cordotomy, implantable pumps",
    "chunk_index": 84
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_85",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain management: early/supportive palliative referrals, cordotomy, radiotherapy palliation predictors",
    "chunk_index": 85
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_79",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Palliative radiotherapy for cancer pain: bone metastases dosing, single‑fraction benefits, patient selection",
    "chunk_index": 79
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_86",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Painful bone metastases: single‑ vs multifraction palliative radiotherapy efficacy and retreatment",
    "chunk_index": 86
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_82",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Radionuclide therapy for osteoblastic metastases: Sr-89/Sm-153 efficacy, flare management, myelosuppression, contraindications",
    "chunk_index": 82
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_87",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Palliative bone‑metastasis pain: radiotherapy, dexamethasone prophylaxis, samarium‑153 evidence",
    "chunk_index": 87
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_90",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Visceral pain: poor localization, referral, sensitization; neuropathic pain less opioid-responsive, alternatives mostly noncancer evidence",
    "chunk_index": 90
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_92",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer neuropathic pain: gabapentin/pregabalin first-line vs TCA/SNRI efficacy and tolerability",
    "chunk_index": 92
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_83",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Radium‑223 in symptomatic castration‑resistant prostate cancer—delays skeletal events, improves survival",
    "chunk_index": 83
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_76",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 77",
    "chunk_index": 76
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_93",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Perioperative pharmacologic prophylaxis for postmastectomy/postthoracotomy neuropathic pain",
    "chunk_index": 93
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_89",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Metastatic bone pain: deep continuous and movement‑triggered incident pain; opioids mainstay, NSAIDs/steroids adjunct, orthopedic evaluation",
    "chunk_index": 89
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_95",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Docetaxel-related peripheral neuropathy in breast cancer: 24-month prevalence and risk factors",
    "chunk_index": 95
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_98",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Scrambler therapy for CIPN: mechanism, RCT pain reduction, sustained to 3 months, no sham control",
    "chunk_index": 98
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_77",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 78",
    "chunk_index": 77
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_94",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Chemotherapy agents causing dose-limiting CIPN—platinum, taxane, vinca, thalidomide; chronic symptoms; immunotherapy neuropathies",
    "chunk_index": 94
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_101",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Geriatric cancer pain management: altered pharmacokinetics, polypharmacy, start-low dosing",
    "chunk_index": 101
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_96",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Risk factors for long-term taxane CIPN in early-stage breast cancer (age, obesity, preexisting neuropathy, African ancestry)",
    "chunk_index": 96
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_100",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Lumbar puncture–related headache in cancer patients: prevention (atraumatic needle) and treatments (caffeine, gabapentin)",
    "chunk_index": 100
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_103",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Geriatric cancer pain: lower opioid doses, higher sedation/constipation; avoid TCAs; use duloxetine/gabapentin",
    "chunk_index": 103
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_97",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "CIPN management: gabapentin monotherapy ineffective; TCA/topical trial reasonable; scrambler caution",
    "chunk_index": 97
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_88",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Neuropathic and acute procedural cancer pain management (CIPN, postmastectomy/postthoracotomy, biopsy); geriatric decision considerations",
    "chunk_index": 88
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_104",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Assessment and adjuvant analgesic evidence for bone and neuropathic cancer pain",
    "chunk_index": 104
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_107",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Prevention of persistent post‑thoracotomy pain and chemo‑induced neuropathy (gabapentin, cryoanalgesia, venlafaxine)",
    "chunk_index": 107
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_106",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Persistent postmastectomy/post‑thoracotomy pain: IV lidocaine, paravertebral block, TENS trials",
    "chunk_index": 106
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_110",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Oncology procedural sedation (marrow/LP) and post‑lumbar puncture headache prevention; geriatric analgesic guidance",
    "chunk_index": 110
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_108",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Taxane/platinum chemotherapy–CIPN: risk factors, GWAS, racial disparities, prevention/management trials",
    "chunk_index": 108
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_111",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Elderly cancer patients: age-related pain physiology and analgesic pharmacology (hepatic impairment)",
    "chunk_index": 111
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_91",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 92",
    "chunk_index": 91
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_105",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Neuropathic cancer pain: anticonvulsant/antidepressant adjuncts vs opioids; postmastectomy psychosocial predictors",
    "chunk_index": 105
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_99",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "CIPN: scrambler therapy vs TENS efficacy; bone marrow biopsy procedural analgesia options",
    "chunk_index": 99
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_113",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Editorial board consensus update process; levels of evidence and citation/contact",
    "chunk_index": 113
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_114",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Cancer pain — image licensing, citation, syndication, insurance disclaimer, contact",
    "chunk_index": 114
  },
  {
    "chunk_id": "dba3b1192d9c4e3c8a23cfdb618bb415_chunk_0",
    "doc_title": "NIH/NHLBI — Asthma Management Guidelines: Focused Updates 2020",
    "source_url": "https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates",
    "ctx_header": "Asthma long-term management: LAMA added to inhaled corticosteroid; indoor trigger reduction",
    "chunk_index": 0
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_1",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Biennial screening age 40–74 (B); urgent research on disparities, dense breasts, older women",
    "chunk_index": 1
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_3",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Dense breasts: supplemental ultrasound/MRI evidence insufficient; screen biennially from age 40",
    "chunk_index": 3
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_112",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "PDQ cancer pain updates: monthly board review, citation/replacement criteria, editorial independence",
    "chunk_index": 112
  },
  {
    "chunk_id": "dba3b1192d9c4e3c8a23cfdb618bb415_chunk_1",
    "doc_title": "NIH/NHLBI — Asthma Management Guidelines: Focused Updates 2020",
    "source_url": "https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates",
    "ctx_header": "Asthma 2020 updates: allergen immunotherapy, FeNO testing, bronchial thermoplasty (selected adults)",
    "chunk_index": 1
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_4",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Women 40–74: USPSTF recommends biennial screening mammography (Grade B); 75+ insufficient evidence",
    "chunk_index": 4
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_102",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 103",
    "chunk_index": 102
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_0",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF recommends biennial mammography from age 40 for all women; research urged",
    "chunk_index": 0
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_5",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Biennial mammography for average‑risk AFAB/cisgender women 40–74 (Grade B); 75+ evidence insufficient (Grade I)",
    "chunk_index": 5
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_7",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer screening: clinician individualized decision-making and evidence/resources",
    "chunk_index": 7
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_2",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Biennial screening ages 40–74 (grade B); urgent research: disparities, dense breasts, older women",
    "chunk_index": 2
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_8",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer screening recommendation framework: benefits vs harms, no cost consideration, equity",
    "chunk_index": 8
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_11",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "DBT with 2D/synthetic vs digital mammography: similar detection, slight PPV gain; biennial over annual",
    "chunk_index": 11
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_13",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Black women — higher breast cancer mortality; structural/environmental drivers and triple-negative risk",
    "chunk_index": 13
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_15",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer screening: racial/ethnic follow-up gaps, endocrine therapy discontinuation, ≥75y evidence uncertain",
    "chunk_index": 15
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_16",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Women with dense breasts: insufficient evidence for supplemental ultrasound or MRI screening",
    "chunk_index": 16
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_9",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "US women breast cancer epidemiology: incidence trends, racial disparities ages 40–49",
    "chunk_index": 9
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_12",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Screen-detected DCIS — overdiagnosis uncertainty and variable treatment choices",
    "chunk_index": 12
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_109",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "ctx_header": "Medical content from Section 110",
    "chunk_index": 109
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_17",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF update: mammography screening ages, modalities, and evidence gaps in women (dense breasts, ≥75)",
    "chunk_index": 17
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_19",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "CISNET modeling of age/modality/interval screening tradeoffs; Black‑women race‑specific analyses",
    "chunk_index": 19
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_10",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Mammography screening: AFAB/cisgender women ≥40 at average risk; excludes BRCA, chest radiation, prior breast cancer",
    "chunk_index": 10
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_20",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Randomized-trial evidence: age-stratified mammography mortality reductions; old trials, few Black participants, no all-cause benefit",
    "chunk_index": 20
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_21",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Mammography cessation effects on breast cancer mortality ages 70–84 — trial emulation and modeling",
    "chunk_index": 21
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_6",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Biennial digital/DBT mammography for average‑risk women 40–74; excludes BRCA/high‑risk",
    "chunk_index": 6
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_24",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Biennial vs annual mammography: modeling favors biennial for all/Black women; DBT lacks mortality RCTs",
    "chunk_index": 24
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_26",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Overdiagnosis estimates for breast screening; biennial 40–74 modeling (11–19%; ~14/1000)",
    "chunk_index": 26
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_27",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Stopping mammography at ≥70 vs continued annual screening — diagnoses, overdiagnosis, false positives",
    "chunk_index": 27
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_18",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Mammography screening comparative-effectiveness review; age/interval/modality, stage‑shift inclusion criteria",
    "chunk_index": 18
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_29",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Interval cancer rates: three RCTs comparing DBT vs digital mammography show no significant difference",
    "chunk_index": 29
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_31",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "DBT vs digital mammography: higher radiation; MRI adjunct in extremely dense breasts lowers interval cancers but increases cascades",
    "chunk_index": 31
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_14",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Medical content from Section 15",
    "chunk_index": 14
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_32",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Adjunctive breast ultrasound vs digital mammography in ages 40–49: no interval cancer benefit; higher biopsy/false-positive rates",
    "chunk_index": 32
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_30",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Women 40–74 screening: DBT vs digital mammography — lower false positives, similar DCIS",
    "chunk_index": 30
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_34",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Average‑risk women: biennial versus annual mammography — trials inconclusive; modeling favors biennial",
    "chunk_index": 34
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_33",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Age limits and risk‑based screening evidence gaps: no trials ≥75, none <39, trials ongoing",
    "chunk_index": 33
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_35",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Dense-breast supplemental MRI/US: insufficient evidence; I-statement excludes BRCA/chest‑radiation high‑risk women",
    "chunk_index": 35
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_28",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Screening interval effects (ages 40–74): interval cancers, false-positives, overdiagnosis",
    "chunk_index": 28
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_39",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF authorship, COI recusal, and JAMA citation for breast cancer screening recommendation",
    "chunk_index": 39
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_23",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Annual vs biennial/triennial mammography outcomes evidence (women 40–49)",
    "chunk_index": 23
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_36",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Screening disparities in Black women: biomarker patterns, higher mortality, research priorities",
    "chunk_index": 36
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_40",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF disclosures: conflicts of interest and AHRQ funding for breast screening",
    "chunk_index": 40
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_25",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Medical content from Section 26",
    "chunk_index": 25
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_38",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Professional society screening recommendations: ACS 45; ACOG 40; ACR risk assessment by 25; AAFP supports USPSTF",
    "chunk_index": 38
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_44",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Moderate-certainty biennial mammography net benefit ages 40–74; 75+ and supplemental insufficient",
    "chunk_index": 44
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_43",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Female breast cancer incidence and SEER data by age and race",
    "chunk_index": 43
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_37",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF rationale: biennial mammography 40–74, decision-modeling on benefit–harm balance",
    "chunk_index": 37
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_22",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Medical content from Section 23",
    "chunk_index": 22
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_47",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "USPSTF research priorities—supplemental screening in dense breasts; DCIS natural history; Black women disparities",
    "chunk_index": 47
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_42",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Reproduction and commercial-use restrictions plus citation requirement for USPSTF materials",
    "chunk_index": 42
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_0",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical LLM instruction‑finetuning: dataset diversity limits clinical generalizability",
    "chunk_index": 0
  },
  {
    "chunk_id": "17a50c3469054612a8a02144f4c118a1_chunk_1",
    "doc_title": "NIH/NHLBI — Asthma Management Guidelines: Focused Updates 2020",
    "source_url": "https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates",
    "ctx_header": "Asthma interventions: allergy immunotherapy, FeNO diagnostics, bronchial thermoplasty (selected adults)",
    "chunk_index": 1
  },
  {
    "chunk_id": "17a50c3469054612a8a02144f4c118a1_chunk_0",
    "doc_title": "NIH/NHLBI — Asthma Management Guidelines: Focused Updates 2020",
    "source_url": "https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates",
    "ctx_header": "Asthma long-term management: ICS, add-on LAMA, indoor trigger control",
    "chunk_index": 0
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_1",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Multi-specialty clinician-curated seed tasks for GPT-4 semi-automated IFT dataset",
    "chunk_index": 1
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_46",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer screening — evidence gaps: DCIS natural history, prognostic indicators, Black women equity",
    "chunk_index": 46
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_2",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical-education instruction generation: clinician-seeded GPT-4 synthesis to 52K filtered tasks",
    "chunk_index": 2
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_7",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "MedInstruct-52K instruction diversity, verb–noun entropy and annotation consensus",
    "chunk_index": 7
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_8",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Fatigue and hair loss: initial differential diagnosis and indications for clinical workup",
    "chunk_index": 8
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_41",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Breast cancer screening: AHRQ support, USPSTF independence, copyright and redistribution restrictions",
    "chunk_index": 41
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_3",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "AlpaCare vs instruction-tuned baselines pairwise GPT-3.5 auto-eval on MedInstruct-52k",
    "chunk_index": 3
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_11",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical QA datasets and instruction-tuning methods for LLM training",
    "chunk_index": 11
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_45",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "ctx_header": "Insufficient evidence: screening mammography in women ≥75; supplemental ultrasound/MRI after negative mammogram (any density)",
    "chunk_index": 45
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_6",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical question-answering: AlpaCare 13B superior on correctness and helpfulness",
    "chunk_index": 6
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_13",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical instruction dataset generation; teacher LLM hallucination risk; clinician-rated difficulty",
    "chunk_index": 13
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_10",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical LLM benchmarks, conversational datasets, and generalist-vs-specialist comparisons",
    "chunk_index": 10
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_12",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Healthcare QA datasets and LLM benchmarking for instruction tuning",
    "chunk_index": 12
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_9",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Instruction-finetuned medical LLMs: model cards, evaluation frameworks, key citations",
    "chunk_index": 9
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_18",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "AlpaCare vs Alpaca medical-instruction benchmark across LLM backbones and judges",
    "chunk_index": 18
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_17",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical instruction-tuned LLM benchmarking: MedInstruct-test difficulty and AlpacaFarm reference-model evaluation",
    "chunk_index": 17
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_15",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Task-generation prompt for MedInstruct‑52k: diverse medical task templates (viewpoints, formats, difficulty)",
    "chunk_index": 15
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_14",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical-case difficulty scoring rubric — tasks from trivial facts to complex diagnostic management",
    "chunk_index": 14
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_5",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical content from Section 6",
    "chunk_index": 5
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_4",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical content from Section 5",
    "chunk_index": 4
  },
  {
    "chunk_id": "f7ecae41fb9748eeba34594533854e1d_chunk_16",
    "doc_title": "medical_paper",
    "source_url": "medical_paper.pdf",
    "ctx_header": "Medical content from Section 17",
    "chunk_index": 16
  }
]